Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression

In a groundbreaking study published in the Proceedings of the National Academy of Sciences, researchers have identified a novel therapeutic target for cancer treatment using a cutting-edge technique called Cell-SELEX. This workflow, which integrates single-cell expression analysis with aptamer selection, has led to the discovery of a high-affinity aptamer, CW06, and its target, the membrane protein SLC25A24. The findings not only highlight a promising new avenue for cancer research but also reveal a potential mechanism for antitumor effects, offering hope for improved treatment options.

The study begins with the identification of the aptamer CW06, which was selected through a process of screening for high-affinity binding to an unidentified target. Aptamers are short single-stranded DNA or RNA molecules that can bind specifically to target proteins, and they have been increasingly explored as potential therapeutic agents due to their high specificity and ease of modification. However, a major challenge in developing aptamer-based therapies has been the identification of suitable targets.

To address this challenge, the researchers employed Cell-SELEX, a technique that combines single-cell RNA sequencing with aptamer selection. This approach allows for the identification of cell surface proteins that are expressed in cancer cells and can be targeted by aptamers. By applying Cell-SELEX, the researchers were able to pinpoint SLC25A24 as the target of CW06. SLC25A24, also known as mitochondrial calcium uniporter 2, is a membrane protein involved in calcium homeostasis within cells.

The study further explores the therapeutic potential of CW06 and SLC25A24. Researchers found that the aptamer exerts antitumor effects by inhibiting the function of SLC25A24. This inhibition disrupts calcium signaling pathways that are crucial for cancer cell proliferation and survival. By targeting SLC25A24, CW06 can potentially suppress tumor growth and induce apoptosis in cancer cells.

The researchers conducted in vitro and in vivo experiments to validate the antitumor effects of CW06. In cell culture studies, they observed that CW06 treatment led to a significant reduction in cancer cell proliferation and increased apoptosis. Furthermore, in mouse models of cancer, the aptamer demonstrated efficacy in slowing tumor growth and improving survival rates. These results suggest that CW06 could serve as a promising therapeutic agent for cancer treatment.

The identification of SLC25A24 as a therapeutic target through the Cell-SELEX workflow represents a significant advancement in the field of cancer research. This integrated approach not only streamlines the process of discovering aptamer targets but also provides insights into the molecular mechanisms underlying the antitumor effects of the aptamer. The study underscores the potential of aptamers as a new class of cancer therapies, offering a more targeted and potentially less toxic alternative to traditional chemotherapy.

In conclusion, the discovery of CW06 and its target SLC25A24 through the Cell-SELEX workflow offers a promising new strategy for cancer treatment. By targeting a membrane protein involved in calcium signaling, the aptamer can inhibit cancer cell proliferation and induce apoptosis, demonstrating significant antitumor potential. This research not only highlights the importance of innovative techniques like Cell-SELEX in identifying therapeutic targets but also emphasizes the potential of aptamers as a valuable tool in the fight against cancer. As further studies are conducted, this discovery could pave the way for the development of more effective and personalized cancer therapies.